NCT05556005

Efficacy of Trimetazidine in Diabetic Patients

Effect Of Trimetazidine On Left Ventricular Functions and Inflammatory Markers of Patients With Type 2 Diabetes Mellitus

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Subclinical diastolic dysfunction represents the early phase of diabetic cardiomyopathy and is a common complication among type 2 diabetic patients that increases mortality rate among those patients and can progress to heart failure with preserved ejection fraction. Trimetazidine is an anti-ischemic agent widely used in the treatment of coronary artery disease and it has positive effects on energy metabolism in heart failure. Therefore, we hypothesized that trimetazidine may have potential benefit on the amelioration of the inflammatory insult and improving the clinical outcomes in patients with diabetic cardiomyopathy especially if applied in the early stages.

Conditions

• Diabetes Mellitus, Type 2
• Diabetic Cardiomyopathies

Interventions

Type	Name	Description
DRUG	Trimetazidine Dihydrochloride	Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
DRUG	Placebo	Starch tablets used twice daily

Timeline

• Start date: 2022-09-18
• Primary completion: 2023-09-01
• Completion: 2023-09-01
• First posted: 2022-09-27
• Last updated: 2022-09-27

Locations

1 site across 1 country: Egypt